Page last updated: 2024-09-05

s 16020-2 and Leukemia L 1210

s 16020-2 has been researched along with Leukemia L 1210 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anstett, M; Atassi, G; Bisagni, E; Casabianca-Pignede, MR; Léonce, S; Perez, V; Pierré, A	1

Other Studies

1 other study(ies) available for s 16020-2 and Leukemia L 1210

Article	Year
In vitro cytotoxicity of S16020-2, a new olivacine derivative. Investigational new drugs, 1996, Volume: 14, Issue:2 Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Division; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Ellipticines; Ethidium; Humans; Isoenzymes; Leukemia L1210; Mice; Neoplasms; Neoplasms, Experimental; Neoplastic Stem Cells; Phenotype; Tumor Cells, Cultured	1996

Article

Year

In vitro cytotoxicity of S16020-2, a new olivacine derivative.

Investigational new drugs, 1996, Volume: 14, Issue:2

Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Division; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Ellipticines; Ethidium; Humans; Isoenzymes; Leukemia L1210; Mice; Neoplasms; Neoplasms, Experimental; Neoplastic Stem Cells; Phenotype; Tumor Cells, Cultured

1996